Full Breakdown
Israeli Researchers Repurpose CAR-T Therapy for Alzheimer’s Disease
2/10/2026, 3:58:12 AM
Breakthrough in Alzheimer’s Treatment
An international research team led by scientists from the Weizmann Institute of Science and Washington University School of Medicine has achieved a significant breakthrough by repurposing CAR T-cell therapy, originally developed for blood cancers, to target Alzheimer’s disease. This innovative approach, detailed in a peer-reviewed study published in the *Proceedings of the National Academy of Sciences*, demonstrates promising results in a mouse model of Alzheimer’s, potentially paving the way for new treatments for this debilitating neurodegenerative disorder.
The Science Behind the Research
The study, spearheaded by Prof. Ido Amit from Weizmann and Prof. Jonathan Kipnis from Washington University, involved genetically engineering T cells from healthy mice to recognize and respond to amyloid-beta proteins, which accumulate in the brains of Alzheimer’s patients. The researchers injected these modified T cells into mice exhibiting amyloid-beta plaques, leading to a significant reduction in plaque deposits and decreased markers of inflammation in brain tissue. This marks the first application of CAR T-cell technology to a neurodegenerative disease, suggesting a novel therapeutic pathway for conditions such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease.
Historical Context and Legacy
The foundation for this research was laid over 30 years ago by Prof. Zelig Eshhar, who developed CAR T-cell therapy. Eshhar's pioneering work has been instrumental in transforming the concept of engineering immune cells into a viable treatment for cancer. Following his passing in July 2023, the current research team has built upon his legacy, emphasizing the potential of CAR T-cell technology beyond oncology.
Future Implications and Research Directions
The implications of this research extend beyond Alzheimer’s disease. Prof. Amit indicated that future studies may explore the use of engineered immune cells to promote recovery from acute brain injuries and facilitate neural repair and regeneration. This could establish CAR T-cell technology as a versatile therapeutic platform for various brain diseases.
Criticism and Challenges Ahead
Despite the promising results, experts caution that translating CAR T-cell strategies from oncology to neurodegenerative diseases poses significant challenges. CAR T treatments can lead to serious side effects, including cytokine release syndrome and neurological toxicities. As such, meticulous safety engineering and careful trial design will be essential in advancing this research into clinical applications.
Verbatim Quotes
- “This research is the first proof of feasibility for treating neurodegenerative brain diseases using CAR-T technology,” — Prof. Jonathan Kipnis, Washington University School of Medicine
- “Eshhar’s ingenious work was developed for blood cancer, and we saw that it has huge potential and took it a step further,” — Prof. Ido Amit, Weizmann Institute of Science
- “In future studies, we expect to demonstrate the use of engineered immune cells in the recovery from acute brain injuries and in promoting neural repair and regeneration,” — Prof. Ido Amit, Weizmann Institute of Science
This groundbreaking research represents a significant step forward in the quest for effective treatments for Alzheimer’s disease and highlights the potential of CAR T-cell therapy in addressing a range of neurodegenerative conditions.
